{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:11:54Z","timestamp":1787587914432,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>There is a need for more precise biomarkers and understanding on the development of aggressive prostate cancer. In this study, we analyzed DNA methylation in 64 prostate cancer tissue samples, using tissue from radical prostatectomy patients (<jats:italic>n<\/jats:italic>\u2009=\u200916) with up to 16 years of clinical follow-up. We used several samples from each patient including both normal and cancer tissue to study DNA methylation patterns in relation to aggressiveness measured by follow-up data of biochemical recurrence and metastasis status as clinical endpoints. We identified differentially methylated CpGs associated with recurrence and metastasis, regardless of whether the tissue was normal, cancer-adjacent normal, or cancer. The identified CpG sites were over-represented in promoter regions and transcription factor binding regions, suggesting their influence on gene expression regulation. They further exhibited low intrapatient heterogeneity both between normal, normal adjacent, and cancer tissue, making them favorable as potential biomarkers for aggressive prostate cancer. However, validation of a subset of these CpGs in an external dataset was unsuccessful.<\/jats:p>","DOI":"10.1186\/s13148-025-01932-x","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:07:53Z","timestamp":1753139273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["DNA methylation in normal-appearing tissue associated with prostate cancer recurrence and metastasis"],"prefix":"10.1186","volume":"17","author":[{"given":"Christine Aaser\u00f8d","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Wess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Midtbust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Viset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"St\u00f8rkersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten B.","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May-Britt","family":"Tessem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"1\u20132","key":"1932_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000477852","volume":"85","author":"Y Tolkach","year":"2018","unstructured":"Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85(1\u20132):108\u201316.","journal-title":"Pathobiology"},{"issue":"6","key":"1932_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neo.2021.05.012","volume":"23","author":"SG Kidd","year":"2021","unstructured":"Kidd SG, Carm KT, Bogaard M, Olsen LG, Bakken AC, L\u00f8vf M, et al. High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity. Neoplasia. 2021;23(6):634\u201341.","journal-title":"Neoplasia"},{"key":"1932_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2016.04.009","volume":"166","author":"CE Massie","year":"2017","unstructured":"Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol. 2017;166:1\u201315.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"15","key":"1932_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/pros.21379","volume":"71","author":"S Bhusari","year":"2011","unstructured":"Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate. 2011;71(15):1621\u201330.","journal-title":"Prostate"},{"issue":"5","key":"1932_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000318017","volume":"77","author":"I Steiner","year":"2010","unstructured":"Steiner I, Jung K, Schatz P, Horns T, Wittschieber D, Lein M, et al. Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology. 2010;77(5):260\u20136.","journal-title":"Pathobiology"},{"issue":"4","key":"1932_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jnci\/djj051","volume":"98","author":"JA Hanson","year":"2006","unstructured":"Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst. 2006;98(4):255\u201361.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1932_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10735-004-6166-7","volume":"36","author":"M Slater","year":"2005","unstructured":"Slater M, Danieletto S, Barden JA. Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol. 2005;36(3):159\u201365.","journal-title":"J Mol Histol"},{"issue":"20","key":"1932_CR8","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1002\/cam4.3419","volume":"9","author":"X Long","year":"2020","unstructured":"Long X, Wu L, Zeng X, Wu Z, Hu X, Jiang H, et al. Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision-making processes. Cancer Med. 2020;9(20):7524\u201336.","journal-title":"Cancer Med"},{"issue":"6","key":"1932_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.juro.2012.11.074","volume":"189","author":"M Truong","year":"2013","unstructured":"Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, et al. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol. 2013;189(6):2335\u201341.","journal-title":"J Urol"},{"issue":"1","key":"1932_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13148-019-0771-5","volume":"11","author":"B Yang","year":"2019","unstructured":"Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, et al. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. Clin Epigenetics. 2019;11(1):168.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1932_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12943-023-01863-2","volume":"22","author":"S Figiel","year":"2023","unstructured":"Figiel S, Yin W, Doultsinos D, Erickson A, Poulose N, Singh R, et al. Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures. Mol Cancer. 2023;22(1):162.","journal-title":"Mol Cancer"},{"issue":"10","key":"1932_CR12","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1158\/1078-0432.CCR-11-2090","volume":"18","author":"S Mahapatra","year":"2012","unstructured":"Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res. 2012;18(10):2882\u201395.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1932_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/pros.21260","volume":"71","author":"H Bertilsson","year":"2011","unstructured":"Bertilsson H, Angelsen A, Viset T, Skogseth H, Tessem M-B, Halgunset J. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy. Prostate. 2011;71(5):461\u20139.","journal-title":"Prostate"},{"issue":"10","key":"1932_CR14","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30(10):1363\u20139.","journal-title":"Bioinformatics"},{"issue":"4","key":"1932_CR15","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/30.4.894","volume":"45","author":"W Zhou","year":"2017","unstructured":"Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45(4): e22.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1932_CR16","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1932_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2013","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013;30(7):923\u201330.","journal-title":"Bioinformatics"},{"key":"1932_CR18","doi-asserted-by":"crossref","unstructured":"Chen Y, Lun A, Smyth G. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline [version 2; peer review: 5 approved]. F1000Research. 2016;5(1438).","DOI":"10.12688\/f1000research.8987.2"},{"issue":"1","key":"1932_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12864-018-4533-0","volume":"19","author":"Y Xi","year":"2018","unstructured":"Xi Y, Shi J, Li W, Tanaka K, Allton KL, Richardson D, et al. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. BMC Genomics. 2018;19(1):150.","journal-title":"BMC Genomics"},{"issue":"D1","key":"1932_CR20","doi-asserted-by":"publisher","first-page":"D882","DOI":"10.1093\/nar\/gkz1062","volume":"48","author":"Y Luo","year":"2020","unstructured":"Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, et al. New developments on the encyclopedia of DNA elements (ENCODE) data portal. Nucleic Acids Res. 2020;48(D1):D882\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1932_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841\u20132.","journal-title":"Bioinformatics"},{"issue":"4","key":"1932_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1210","volume":"47","author":"M Gheorghe","year":"2019","unstructured":"Gheorghe M, Sandve GK, Khan A, Ch\u00e8neby J, Ballester B, Mathelier A. A map of direct TF-DNA interactions in the human genome. Nucleic Acids Res. 2019;47(4): e21.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1932_CR23","doi-asserted-by":"publisher","first-page":"D260","DOI":"10.1093\/nar\/gkx1126","volume":"46","author":"A Khan","year":"2018","unstructured":"Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 2018;46(D1):D260\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"7637","key":"1932_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature20788","volume":"541","author":"M Fraser","year":"2017","unstructured":"Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541(7637):359\u201364.","journal-title":"Nature"},{"issue":"4","key":"1932_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1593\/neo.13280","volume":"15","author":"B Yang","year":"2013","unstructured":"Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia. 2013;15(4):399-IN13.","journal-title":"Neoplasia"},{"key":"1932_CR26","doi-asserted-by":"publisher","first-page":"40636","DOI":"10.1038\/srep40636","volume":"7","author":"M Moller","year":"2017","unstructured":"Moller M, Strand SH, Mundbjerg K, Liang G, Gill I, Haldrup C, et al. Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci Rep. 2017;7:40636.","journal-title":"Sci Rep"},{"issue":"2","key":"1932_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/pros.20675","volume":"68","author":"J Mehrotra","year":"2008","unstructured":"Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate. 2008;68(2):152\u201360.","journal-title":"Prostate"},{"key":"1932_CR28","unstructured":"Matulevi\u010dius A, \u017dukauskait\u0117 K, Gineikait\u0117 R, Dasevi\u010dius D, Trakymas M, Naru\u0161evi\u010di\u016bt\u0117 I, et al. Combination of DNA methylation biomarkers with multiparametric magnetic resonance and ultrasound imaging fusion biopsy to detect the local spread of prostate cancer. The Prostate.n\/a(n\/a)."},{"issue":"2","key":"1932_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189080","volume":"1879","author":"RI Skotheim","year":"2024","unstructured":"Skotheim RI, Bogaard M, Carm KT, Axcrona U, Axcrona K. Prostate cancer: molecular aspects, consequences, and opportunities of the multifocal nature. Biochim Biophys Acta Rev Cancer. 2024;1879(2): 189080.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"1932_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.celrep.2014.06.053","volume":"8","author":"D Brocks","year":"2014","unstructured":"Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014;8(3):798\u2013806.","journal-title":"Cell Rep"},{"issue":"169","key":"1932_CR31","doi-asserted-by":"publisher","first-page":"169ra10","DOI":"10.1126\/scitranslmed.3005211","volume":"5","author":"MJ Aryee","year":"2013","unstructured":"Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5(169):169ra10-ra10.","journal-title":"Sci Transl Med."},{"issue":"8\u20139","key":"1932_CR32","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41417-022-00444-7","volume":"29","author":"JM Str\u00f8mme","year":"2022","unstructured":"Str\u00f8mme JM, Johannessen B, Kidd SG, Bogaard M, Carm KT, Zhang X, et al. Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Ther. 2022;29(8\u20139):1276\u201384.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"1932_CR33","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1158\/1055-9965.EPI-10-0555","volume":"19","author":"T Bianco-Miotto","year":"2010","unstructured":"Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2611\u201322.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"1932_CR34","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/j.celrep.2017.05.069","volume":"19","author":"JF Kribelbauer","year":"2017","unstructured":"Kribelbauer JF, Laptenko O, Chen S, Martini GD, Freed-Pastor WA, Prives C, et al. Quantitative analysis of the DNA methylation sensitivity of transcription factor complexes. Cell Rep. 2017;19(11):2383\u201395.","journal-title":"Cell Rep"},{"issue":"6337","key":"1932_CR35","doi-asserted-by":"publisher","first-page":"eaaj2239","DOI":"10.1126\/science.aaj2239","volume":"356","author":"Y Yin","year":"2017","unstructured":"Yin Y, Morgunova E, Jolma A, Kaasinen E, Sahu B, Khund-Sayeed S, et al. Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science. 2017;356(6337):eaaj2239.","journal-title":"Science"},{"issue":"6","key":"1932_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1042\/EBC20190033","volume":"63","author":"\u00c9 H\u00e9berl\u00e9","year":"2019","unstructured":"H\u00e9berl\u00e9 \u00c9, Bardet AF. Sensitivity of transcription factors to DNA methylation. Essays Biochem. 2019;63(6):727\u201341.","journal-title":"Essays Biochem"},{"issue":"4","key":"1932_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/onc.2015.109","volume":"35","author":"P Adamo","year":"2016","unstructured":"Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2016;35(4):403\u201314.","journal-title":"Oncogene"},{"key":"1932_CR38","doi-asserted-by":"crossref","unstructured":"Belluti S, Imbriano C, Casarini L. Nuclear estrogen receptors in prostate cancer: from genes to function. Cancers (Basel). 2023;15(18).","DOI":"10.3390\/cancers15184653"},{"issue":"36","key":"1932_CR39","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1038\/s41388-020-01418-5","volume":"39","author":"SH Shin","year":"2020","unstructured":"Shin SH, Kim I, Lee JE, Lee M, Park JW. Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. Oncogene. 2020;39(36):5839\u201354.","journal-title":"Oncogene"},{"issue":"1","key":"1932_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-023-01416-y","volume":"9","author":"Z He","year":"2023","unstructured":"He Z, He J, Xie K. KLF4 transcription factor in tumorigenesis. Cell Death Discovery. 2023;9(1):118.","journal-title":"Cell Death Discovery"},{"issue":"6","key":"1932_CR41","doi-asserted-by":"publisher","first-page":"101042831770392","DOI":"10.1177\/1010428317703924","volume":"39","author":"QB Chen","year":"2017","unstructured":"Chen QB, Liang YK, Zhang YQ, Jiang MY, Han ZD, Liang YX, et al. Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer. Tumour Biol. 2017;39(6):1010428317703924.","journal-title":"Tumour Biol"},{"issue":"35","key":"1932_CR42","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1038\/s41388-019-0873-8","volume":"38","author":"L Li","year":"2019","unstructured":"Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019;38(35):6241\u201355.","journal-title":"Oncogene"},{"key":"1932_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153666","volume":"228","author":"Z-Y Zhang","year":"2021","unstructured":"Zhang Z-Y, Zhang S-L, Chen H-L, Mao Y-Q, Kong C-Y, Li Z-M, et al. Low EGR1 expression predicts poor prognosis in clear cell renal cell carcinoma. Pathol Res Pract. 2021;228: 153666.","journal-title":"Pathol Res Pract"},{"issue":"8","key":"1932_CR44","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3727\/096504017X14871164924588","volume":"25","author":"F Chen","year":"2017","unstructured":"Chen F, Xiong W, Dou K, Ran Q. Knockdown of FOXK1 suppresses proliferation, migration, and invasion in prostate cancer cells. Oncol Res. 2017;25(8):1261\u20137.","journal-title":"Oncol Res"},{"issue":"12","key":"1932_CR45","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1158\/0008-5472.CAN-23-1954","volume":"84","author":"F Shu","year":"2024","unstructured":"Shu F, Liu H, Chen X, Liu Y, Zhou J, Tang L, et al. m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB. Cancer Res. 2024;84(12):1947\u201362.","journal-title":"Cancer Res"},{"issue":"21","key":"1932_CR46","doi-asserted-by":"publisher","first-page":"8954","DOI":"10.1158\/0008-5472.CAN-07-6088","volume":"68","author":"S Yegnasubramanian","year":"2008","unstructured":"Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68(21):8954\u201367.","journal-title":"Cancer Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01932-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01932-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01932-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:06:05Z","timestamp":1757271965000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01932-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01932-x","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas Fleischer, which is a co-author of this manuscript is an associate editor in Clinical Epigenetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}